Samira Syed

Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors

Alain C. Mita, Lisa A. Hammond, Peter L. Bonate et al. · Clinical Cancer Research · 2006 · 66 citations · Full text

A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties

Samira Syed, Chris H. Takimoto, Manuel Hidalgo et al. · Clinical Cancer Research · 2004 · 64 citations

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

Quincy Chu, Bahram Forouzesh, Samira Syed et al. · Investigational New Drugs · 2007 · 60 citations

Matrix Metalloproteinase Inhibitor, Phase Ii, Malignant Disease +9

Transgenic Expression of the Human MRP2 Transporter Reduces Cisplatin Accumulation and Nephrotoxicity in Mrp2-Null Mice

Wen Xia, Brian Buckley, Elizabeth McCandlish et al. · American Journal Of Pathology · 2014 · 60 citations · Full text

Human Mrp2 Gene, Urology, Kidney Research +13

Multidisciplinary Teams Improve Gastric Cancer Treatment Efficiency at a Large Safety Net Hospital

Michelle R. Ju, Sam C. Wang, Samira Syed et al. · Annals of Surgical Oncology · 2019 · 28 citations

Gastrointestinal Oncology, Medicine, Patient Safety +9